Objective: This study aimed to determine local control and overall survival of patients with medically inoperable early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.
INTRODUCTION
Lung cancer is the deadliest cancer type in both men and women. [1] Surgery is the standard treatment method for early-stage lung cancer. [2] Increased awareness and increased use of screening by tomography have led to increased incidence of cases with early-stage lung cancer. [1, 2] The number of patients who cannot be medically operated is increasing with the increase in elderly population. In this group of patients who could not undergo surgery due to medical reasons, classical fractionated radiotherapies were applied, but the results were not as successful as obtained by surgery. [3] High dose fractionated radiotherapy focusing on tumor can be applied safely and more frequently due to the development in radiotherapy technologies with the guidance of imaging and treatment planning. [4, 5] Basically, stereotactic radiotherapy can be described as an image guided delivery of multiple bundles of high-dose radiation beams on tumors localized three-dimensionally. [6, 7] Stereotactic radiotherapy was first used in treating localized brain tumors in the 1990s, and with the advent of imaging and computer technologies, stereotactic radiotherapy have been successfully applied to tumors located in other organs of the body besides extracranial regions. [6, 7] Currently, stereotactive ablative body radiotherapy (SABR) is an alternative to surgery in patients with non-small cell lung cancer who are medically inoperable or do not accept surgical resection and for small tumors with no lymph node involvement. [7] [8] [9] MATERIAL AND METHODS Thirty-five patients diagnosed with early stage non-small cell lung cancer and not suitable for surgery due to medical comorbidities were treated with CyberKnife radiotherapy machine and were analyzed retrospectively.
Several parameters such as age, sex, tumor localization, T stage, performance scores, planned target volume, system used for tumor tracking, number of fractions, prescribed radiation dose, follow-up times, survival, local relapse, and treatment-related toxicities were evaluated in these patients.
Three different tumor-tracking modalities such as X-Sight lung, gold marker, and X-Sight spine can be used as tracking systems in SABR with CyberKnife. The X-Sight lung tumor tracking method is a non-invasive and reliable method in case when the tumor diameter is greater than 1.5 cm, and tumor is peripherally located and not masked by vertebras and heart. The X-Sight spine technique is another noninvasive tumor-tracking method that can be used safely for tumors situated adjacent to the vertebral bones. Since the gold marker placement method is performed by an interventional radiologist and it has a pneumothorax risk, other tumor tracking modalities are preferred if possible.
In our hospital, all patients with lung cancer who were treated with SABR were evaluated in a multidisciplinary tumor board including chest surgeon, interventional radiologist, and medical and radiation oncologists. Medical inoperability criteria were considered as FEV1 <1.5L, preoperavitiy FEV1 <40%, or DLCO <40%. The last decision was made by thoracic surgeon. The cases that were not operated because of cardiac and other medical reasons were evaluated for stereotactic radiotherapy.
The gross tumor volume (GTV) was determined by making a fusion with Positron emission tomogrophy (PET) on planning tomography in the parenchyma window. PTV was obtained by giving 5 mm margin to GTV due to setup uncertainties and tumor movement. The average tumor volume in the cases was 124.1 mm 3 (14.5-233.7 mm ).
An average of 43 Gy (30-60 Gy) radiotherapy was defined to 81% isodose line (70%-92%) and delivered in 3 and 5 fractions to 33 (94%) and 2 (6%) patients, respectively.
In patients, the time elapsed until local progression, average survival time, and acute toxicity rates were statistically evaluated. The Kaplan-Meier method was used in the survival analysis. Age, performance score, T stage, PTV, dose effect parameters regarding general survival, and local control were assessed with a univariate analysis.
RESULTS
The median age of the cases was 69 (55-83) years [6 (17%) females and 29 (83%) males]. Twenty-four patients (67%) had ECOG performance score of 1, and eleven patients (32%) had 2. The tumor was staged as cT1 (54%) in 19 patients and cT2 (46%) in 16 patients. Tumor location was central in 6 patients (17%), and peripheral in 29 patients (83%). The average PTV volume was 124.1 mm³ (14.5-233.7 mm³).
As tumor tracking system, X-Sight lung method was used in 31 (88%) patients, gold markers in 3 (9%) patients, and X-sight spine method in 1 (3%) patient. An average of 43 Gy (30-60 Gy) radiotherapy was defined to 81% isodose line (70%-92%) and delivered in 3 and 5 fractions to 33 (94%) and 2 (6%) patients, respectively. Patient and treatment characteristics were summarized in Table 1 .
After 21-month mean follow-up time (2-51 months), local relapse was detected in only two patients (5%). The 2-year local control rate was 93.4%. The 2-year survival rate was 45%, and the average survival time was found as 21.4 months. Grade 3 toxicity was detected in two patients, and no grade 4-5 toxicity was detected. These results were shown in Table 2 .
Effect of age, performance score, tumor stage, PTV volume, and radiation dose on overall survival and local control were assessed, but no significance was detected.
The local control and general survival curves are summarized in Figures 1 and 2 .
DISCUSSION
In recent years, remarkable changes occurred in earlystage non-small cell lung cancer in parallel with the development in the fields of surgery and radiotherapy. Currently, the application of video-assisted thoracoscopic surgery has significantly reduced surgery-associated morbidities. Conventional fractionated radiotherapy in treating earlystage lung cancer has left its place to stereotactic ablative body radiotherapy, and SABR is the standard treatment for T1,2 tumors (in cases with no lymph node involvement) that cannot be surgically treated for medical reasons. [10] The local control rates obtained with SABR are very good and are similar to those obtained with surgery. [9, 10] In the present study, only 2 cases out of 35 patients showed post-treatment failure, and the 2-year local control rate was 93.4% ( Figure 1) . Although local control rates were high, the overall survival rate was low in the present study (2-year total survival, 45%). Despite the high success in local control rates, the survival rate is low due to the high non cancer related deaths in these patients. Although local control rates that were obtained with SABR were similar to the rates obtained after surgery, this treatment is still not considered as a standart treatment. This treatment modality is preferred primarily in patients who have comorbidities and are medically inoperable. However, the number of cases who are treated with this technology is rapidly increasing. Current randomized studies in patients with no comorbidities have shown the equivalance of SABR to surgical resection. [4, 11] Another advantage of SABR is the low toxicity rates of this treatment modality, and its easy and safe application in experienced centers. No grade IV toxicity was observed in any of the 35 patients treated in in this study.
In the near future, SABR will become an alternative to surgery, and it will be safely applicable treatment method for cases with early-stage lung cancer. 
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